Rhythm Pharmaceuticals’ (RYTM) Buy Rating Reaffirmed at HC Wainwright

Rhythm Pharmaceuticals (NASDAQ:RYTM)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $70.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 32.30% from the stock’s previous close. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.18) EPS.

Several other analysts have also recently issued reports on RYTM. Morgan Stanley reiterated an “overweight” rating and issued a $72.00 target price on shares of Rhythm Pharmaceuticals in a research note on Friday, March 7th. Needham & Company LLC increased their price objective on Rhythm Pharmaceuticals from $64.00 to $66.00 and gave the stock a “buy” rating in a research report on Tuesday, March 18th. Canaccord Genuity Group lifted their price objective on Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Stifel Nicolaus initiated coverage on Rhythm Pharmaceuticals in a research note on Wednesday, March 5th. They issued a “buy” rating and a $78.00 target price on the stock. Finally, Oppenheimer assumed coverage on Rhythm Pharmaceuticals in a research report on Friday, December 20th. They set an “outperform” rating and a $76.00 price target for the company. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, Rhythm Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $69.46.

Rhythm Pharmaceuticals Stock Performance

NASDAQ:RYTM opened at $52.91 on Monday. The business’s fifty day moving average is $55.28 and its 200 day moving average is $54.99. The firm has a market cap of $3.35 billion, a price-to-earnings ratio of -12.22 and a beta of 2.30. Rhythm Pharmaceuticals has a 52-week low of $35.17 and a 52-week high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million for the quarter, compared to the consensus estimate of $38.48 million. Equities analysts predict that Rhythm Pharmaceuticals will post -4.32 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Yann Mazabraud sold 75,000 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the transaction, the executive vice president now owns 40,370 shares of the company’s stock, valued at approximately $2,078,247.60. This trade represents a 65.01 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Hunter C. Smith sold 1,678 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total transaction of $99,723.54. Following the completion of the sale, the chief financial officer now directly owns 101,186 shares of the company’s stock, valued at $6,013,483.98. This represents a 1.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 108,131 shares of company stock valued at $5,781,098. 5.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Loomis Sayles & Co. L P bought a new stake in Rhythm Pharmaceuticals in the third quarter valued at approximately $33,353,000. Janus Henderson Group PLC raised its holdings in Rhythm Pharmaceuticals by 103.9% during the 4th quarter. Janus Henderson Group PLC now owns 1,219,554 shares of the company’s stock valued at $68,309,000 after buying an additional 621,432 shares during the last quarter. Marshall Wace LLP raised its holdings in Rhythm Pharmaceuticals by 70.4% during the 4th quarter. Marshall Wace LLP now owns 692,803 shares of the company’s stock valued at $38,783,000 after buying an additional 286,188 shares during the last quarter. Norges Bank purchased a new stake in Rhythm Pharmaceuticals during the 4th quarter valued at $11,512,000. Finally, JPMorgan Chase & Co. grew its holdings in Rhythm Pharmaceuticals by 224.3% in the 4th quarter. JPMorgan Chase & Co. now owns 264,585 shares of the company’s stock worth $14,811,000 after acquiring an additional 182,993 shares during the last quarter.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.